Patient Information Leaflets (PILs)
These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD).
The BAD has been awarded The Information Standard certification for the process it employs to develop information products aimed at the general public, which include PILs, Sun Awareness Campaign materials, and other information products.
The BAD shall hold responsibility for the accuracy of the information published, and neither the scheme operator nor the scheme owner shall have any responsibility for costs, losses, or direct or indirect damages or costs arising from inaccuracy of information or omissions in information published on the website on behalf of the BAD.
There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
The offer to provide details of source materials used to inform the British Association of Dermatologists' PILs is for instances where the advice provided in the PILs does not reflect local practice and therefore evidence supporting said advice needs to be produced. It is not an offer to conduct literature searches or supply bibilographic materials for your own research.
For the latest BAD advice on Covid-19 for patients, please check the News and Media section of the website. Find this here. Our information for healthcare professionals is here.
Mucous membrane pemphigoid
MMP is the most up-to-date term for this condition. Other names include cicatricial pemphigoid, oral pemphigoid and ocular pemphigoid.
MMP is an uncommon blistering condition which most frequently affects the lining of the mouth and gums. Other moist surfaces of the body (known as mucous membranes) can also be affected, and these include the surface layers of the eyes, the inside of the nose, the throat and the genitalia. The skin is sometimes affected by a few scattered blisters. MMP usually starts in middle and old age. Although it is not usually a serious condition in the mouth, the diagnosis of any type of MMP is important as it will alert your specialist to the possibility that the condition may involve your eyes, even if you have no symptoms. Eye involvement (known as ocular cicatricial pemphigoid or ocular MMP) does not occur in all people with MMP, but is potentially serious as it may cause scarring and affect your eyesight. Scarring may also affect the throat and the genitalia, and may be very serious if the larynx is affected.
Pemphigoid is a rare blistering disorder, which usually occurs in later life, the average age of onset being over 70 years. The blisters come up on the skin and, less often, in the mouth too. This is in contrast to a related condition known as ‘mucous membrane pemphigoid’ in which the brunt of the trouble is borne by the moist surfaces of the body (the mucous membranes) such as the eyes, inside the nose and mouth, and the genitals.
Rituximab is a medicine known as a biological therapy or ‘biologic’. It reduces the number of a type of blood cell which defends the body against infection. These are known as immune cells or B cells. Rituximab does this by binding to a protein called CD20 on their surface. B cells can cause diseases known as inflammatory and autoimmune conditions. B cells do this by producing harmful autoantibodies. Autoantibodies are proteins produced by the immune system against our own tissues and cause inflammation. By removing B cells, autoantibody levels are reduced, and inflammation and its effects can be reduced.